Yea Christopher

CHIEF DEVELOPMENT OFFICERKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed Jun 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
1 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)230K$00

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 11, 2026Disposed to issuer(D)54K0
Jun 11, 2026Disposed to issuer(D)53K0
Jun 11, 2026Disposed to issuer(D)28K0
Jun 11, 2026Disposed to issuer(D)60K0
Jun 11, 2026Disposed to issuer(D)31K0
Jun 11, 2026Disposed to issuer(D)20K0
Jun 11, 2026Disposed to issuer(D)19K0
Jun 11, 2026Disposed to issuer(D)80K0
Jun 11, 2026Disposed to issuer(D)25K0
Jun 11, 2026Disposed to issuer(D)41K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001691102-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about KALV insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001691102-26-000009"
Ask your agent
Use Arkolith to summarize insider buying and selling at KalVista Pharmaceuticals, Inc.
over the last 90 days and cite the filings.